Efficacy and safety of biosimilar filgrastim in primary and secondary prevention of febrile neutropenia

Kraj,Leszek; Krawczyk‑Lipiec,Joanna; Górniewska,Joanna; Orlik,Grzegorz

doi:10.3892/br.2017.938

Efficacy and safety of biosimilar filgrastim in primary and secondary prevention of febrile neutropenia

Authors:
- Leszek Kraj
- Joanna Krawczyk‑Lipiec
- Joanna Górniewska
- Grzegorz Orlik
View Affiliations

Affiliations: Department of Hematology, Oncology and Internal Diseases, The Medical University of Warsaw, Warsaw 02‑097, Poland, Accord Healthcare Polska Sp. z o.o., Warsaw 02‑677, Poland
Published online on: July 4, 2017 https://doi.org/10.3892/br.2017.938
Pages: 143-147

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Neutropenia and febrile neutropenia (FN) are among the most common side effects/complications of chemotherapy. The aim of the present study was to evaluate the practice of the use of biosimilar filgrastim in the primary and secondary prevention of FN, and assess its efficacy and safety. A multi‑center, non‑interventional epidemiological study of 170 cancer patients aged 23‑82 years was conducted. Data were collected via a questionnaire completed based on medical documentation and patient examination over five chemotherapy visits. The risk of FN related to the chemotherapy protocol used was in the range of 10‑20% in >50% of the patients (53.5%) and a majority (74.7%) had additional FN risk factors. 60% of the patients received filgrastim as primary prevention of FN, and 40% received it as secondary prevention. In 40.6% of cases, six cycles of chemotherapy were used. More than 90% of patients continued chemotherapy according to the initial recommended dose. In majority of patients, no FN was observed following the final cycle of chemotherapy. Median neutrophil count at visit 1 was 2.2x103/µl and did not fall below that level. Majority of patients (>70%) performed self‑injections of filgrastim, and 86.3% of patients were continuing therapy with this drug at the last visit. No treatment‑related side effects were recorded. The use of biosimilar filgrastim in the primary and secondary prevention of FN allows to maintain initial chemotherapy dosage. Furthermore, the use of biosimilar filgrastim is safe and tolerable, and has a high acceptance by patients.

View Figures

View References

1	Crawford J, Caserta C and Roila F: ESMO Guidelines Working Group: Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol. 21 Suppl 5:v248–v251. 2010. View Article : Google Scholar : PubMed/NCBI
2	Dale DC: Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs. 62 Suppl 1:1–15. 2002. View Article : Google Scholar : PubMed/NCBI
3	de Naurois J, Novitzky-Basso I, Gill MJ, Marti FM, Cullen MH and Roila F: ESMO Guidelines Working Group: Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol. 21 Suppl 5:v252–v256. 2010. View Article : Google Scholar : PubMed/NCBI
4	European Commission, . Community register of medicinal products for human use: Accofil. http://ec.europa.eu/health/documents/community-register/html/h946.htmFeb 11–2017
5	Greil R, Psenak O and Roila F: ESMO Guidelines Working Group: Hematopoietic growth factors: ESMO recommendations for the applications. Ann Oncol. 19 Suppl 2:ii116–ii118. 2008. View Article : Google Scholar : PubMed/NCBI
6	Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, et al: European Organisation for Research and Treatment of Cancer: 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 47:8–32. 2011. View Article : Google Scholar : PubMed/NCBI
7	Weise M, Bielsky MC, de Smet K, Ehmann F, Ekman N, Narayanan G, Heim HK, Heinonen E, Ho K, Thorpe R, et al: Biosimilars-why terminology matters. Nat Biotechnol. 29:690–693. 2011. View Article : Google Scholar : PubMed/NCBI
8	Dranitsaris G, Amir E and Dorward K: Biosimilars of biological drug therapies: Regulatory, clinical and commercial considerations. Drugs. 71:1527–1536. 2011. View Article : Google Scholar : PubMed/NCBI
9	Gottlieb S: Biosimilars: Policy, clinical, and regulatory considerations. Am J Health Syst Pharm. 65 Suppl 6:S2–S8. 2008. View Article : Google Scholar : PubMed/NCBI
10	Kuderer NM, Dale DC, Crawford J and Lyman GH: Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systematic review. J Clin Oncol. 25:3158–3167. 2007. View Article : Google Scholar : PubMed/NCBI
11	Blackwell K, Semiglazov V, Krasnozhon D, Davidenko I, Nelyubina L, Nakov R, Stiegler G, Singh P, Schwebig A, Kramer S, et al: Comparison of EP2006, a filgrastim biosimilar, to the reference: A phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy. Ann Oncol. 26:1948–1953. 2015. View Article : Google Scholar : PubMed/NCBI
12	Tesch H, Ulshöfer T, Vehling-Kaiser U, Ottillinger B, Bulenda D and Turner M: Prevention and treatment of chemotherapy-induced neutropenia with the biosimilar filgrastim: A non-interventional observational study of clinical practice patterns. Oncol Res Treat. 38:146–152. 2015. View Article : Google Scholar : PubMed/NCBI
13	Erratum G, ascón P, Aapro M, Ludwig H, Bokemeyer C, Boccadoro M, Turner M, Denhaerynck K, MacDonald K and Abraham I: Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study). Support Care Cancer. 24:911–925. 2016. View Article : Google Scholar : PubMed/NCBI
14	Nahon S, Rastkhah M, Ben Abdelghani M, Soumoudronga RF, Gasnereau I and Labourey JL: Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: A French prospective multicentric study. Support Care Cancer. 24:1991–1998. 2016. View Article : Google Scholar : PubMed/NCBI
15	Bongiovanni A, Monti M, Foca F, Recine F, Riva N, Di Iorio V, Liverani C, de Vita A, Miserocchi G, Mercatali L, et al: Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR). Support Care Cancer. 25:111–117. 2017. View Article : Google Scholar : PubMed/NCBI
16	Verpoort K and Möhler TM: A non-interventional study of biosimilar granulocyte colony-stimulating factor as prophylaxis for chemotherapy-induced neutropenia in a community oncology centre. Ther Adv Med Oncol. 4:289–293. 2012. View Article : Google Scholar : PubMed/NCBI